120 related articles for article (PubMed ID: 37715724)
1. PD-L1 and PD-1 expression in pediatric post-transplant Burkitt lymphoma and other monomorphic post-transplant lymphoproliferative disorders.
Geerlinks AV; Allen U; Ngan BY; Punnett A
Pediatr Blood Cancer; 2023 Dec; 70(12):e30674. PubMed ID: 37715724
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.
Weinberg OK; Pinkus GC; Ramos-Gonzalez GJ; Agur T; Rodig NM
Clin Transplant; 2023 Dec; 37(12):e15134. PubMed ID: 37772613
[TBL] [Abstract][Full Text] [Related]
3. Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.
Stubbins RJ; Lam R; Zhu J; Ghosh S; Mabilangan C; Kuruvilla J; Goswami RS; Lai R; Preiksaitis JK; Jain MD; Peters AC
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):744-752. PubMed ID: 35717340
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
Fisher KE; Ferguson LS; Coffey AM; Merritt BY; Curry JL; Marcogliese AN; Major AM; Kamdar KY; Lopez-Terrada DH; Curry CV
Haematologica; 2022 Aug; 107(8):1880-1890. PubMed ID: 35081690
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.
Schiefer AI; Salzer E; Füreder A; Szepfalusi Z; Müller-Sacherer T; Huber WD; Michel-Behnke I; Lawitschka A; Pichler H; Mann G; Hutter C; Simonitsch-Klupp I; Attarbaschi A
Cancer Med; 2019 Aug; 8(10):4656-4668. PubMed ID: 31269329
[TBL] [Abstract][Full Text] [Related]
7. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
Choi JH; Park BB; Suh C; Won JH; Lee WS; Shin HJ
J Korean Med Sci; 2010 Apr; 25(4):523-6. PubMed ID: 20357991
[TBL] [Abstract][Full Text] [Related]
10. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
11. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
12. High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.
Saito H; Miyoshi H; Shibayama H; Toda J; Kusakabe S; Ichii M; Fujita J; Fukushima K; Maeda T; Mizuki M; Oritani K; Seto M; Yokota T; Kanakura Y; Hosen N; Ohshima K
Int J Hematol; 2021 Jul; 114(1):53-64. PubMed ID: 33765256
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Kinch A; Sundström C; Baecklund E; Backlin C; Molin D; Enblad G
Leuk Lymphoma; 2019 Feb; 60(2):376-384. PubMed ID: 30033844
[TBL] [Abstract][Full Text] [Related]
14. PD-1 Blockade Aggravates Epstein-Barr Virus
Volk V; Theobald SJ; Danisch S; Khailaie S; Kalbarczyk M; Schneider A; Bialek-Waldmann J; Krönke N; Deng Y; Eiz-Vesper B; Dragon AC; von Kaisenberg C; Lienenklaus S; Bleich A; Keck J; Meyer-Hermann M; Klawonn F; Hammerschmidt W; Delecluse HJ; Münz C; Feuerhake F; Stripecke R
Front Oncol; 2020; 10():614876. PubMed ID: 33511078
[TBL] [Abstract][Full Text] [Related]
15. Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience.
Guerra-García P; Bomken S; Ling R; Lazareva A; Gupte G; Amrolia P; Andrés M; Diez-Sebastián J; Taj MM
Pediatr Blood Cancer; 2024 May; ():e31053. PubMed ID: 38757407
[TBL] [Abstract][Full Text] [Related]
16. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.
Courville EL; Yohe S; Chou D; Nardi V; Lazaryan A; Thakral B; Nelson AC; Ferry JA; Sohani AR
Mod Pathol; 2016 Oct; 29(10):1200-11. PubMed ID: 27443517
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
18. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors.
Richendollar BG; Tsao RE; Elson P; Jin T; Steinle R; Pohlman B; Hsi ED
Leuk Lymphoma; 2009 Dec; 50(12):2005-12. PubMed ID: 19860626
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
20. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
